Ekso Bionics Holdings, Inc. (EKSO) Upgraded to Buy at Zacks Investment Research
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday. The firm presently has a $1.25 target price on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 8.70% from the stock’s previous close.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Separately, B. Riley restated a “buy” rating and set a $4.00 target price on shares of Ekso Bionics Holdings in a report on Monday, May 15th.
Shares of Ekso Bionics Holdings (NASDAQ:EKSO) traded down 1.71% during midday trading on Thursday, reaching $1.15. The company had a trading volume of 1,344,570 shares. The company has a 50-day moving average price of $1.57 and a 200 day moving average price of $2.29. Ekso Bionics Holdings has a one year low of $0.99 and a one year high of $6.38. The company’s market capitalization is $29.66 million.
COPYRIGHT VIOLATION NOTICE: “Ekso Bionics Holdings, Inc. (EKSO) Upgraded to Buy at Zacks Investment Research” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/07/ekso-bionics-holdings-inc-ekso-upgraded-to-buy-at-zacks-investment-research.html.
In other Ekso Bionics Holdings news, insider Russ Angold sold 28,254 shares of the stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $1.53, for a total transaction of $43,228.62. Following the sale, the insider now directly owns 250,678 shares of the company’s stock, valued at approximately $383,537.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 259,352 shares of company stock worth $399,373 over the last ninety days. 7.10% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of EKSO. Intellectus Partners LLC lifted its stake in Ekso Bionics Holdings by 5.3% in the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after buying an additional 5,294 shares in the last quarter. Vanguard Group Inc. lifted its stake in Ekso Bionics Holdings by 32.9% in the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after purchasing an additional 176,197 shares in the last quarter. National Planning Corp lifted its stake in Ekso Bionics Holdings by 116.2% in the 2nd quarter. National Planning Corp now owns 234,450 shares of the company’s stock worth $537,000 after purchasing an additional 126,000 shares in the last quarter. Carl Domino Inc lifted its stake in Ekso Bionics Holdings by 74.7% in the 2nd quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock worth $190,000 after purchasing an additional 35,088 shares in the last quarter. Finally, Independence Advisors LLC purchased a new position in Ekso Bionics Holdings in the 2nd quarter worth approximately $1,840,000. 6.04% of the stock is currently owned by institutional investors and hedge funds.
Ekso Bionics Holdings Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.